Neutrophil elastase-IN-7 (Compound 12) is an effective inhibitor of neutrophil elastase (HNE), with an IC50 value of 0.54 μM. Neutrophil elastase-IN-7 also exhibits significant inhibitory activity against various coagulation proteins, with the IC50 values for thrombin, FXa, FXIa, and FXIIIa being 8.2, 12.7, 1.2, and 5.7 μM, respectively. Neutrophil elastase-IN-7 can be used for research on inflammation, innate immune responses, and tissue remodeling.

Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC50 values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

NEURL1B-IN-1 is a NEURL1B degrader with a Kd value of 46.2 nM. NEURL1B-IN-1 binds to Arg422 within the NHR2 domain of NEURL1B, triggers its autoubiquitination and proteasomal degradation, disrupts its interaction with DLL1, and attenuates the Notch signaling pathway. NEURL1B-IN-1 induces cell cycle arrest and apoptosis, and inhibits migration of hepatocellular carcinoma cells. NEURL1B-IN-1 is applicable to research related to hepatocellular carcinoma.

NEPP11 is a cyclopentenone prostaglandin analogue. NEPP11 can inhibit glutamate-induced HT22 cell death in mouse hippocampus and prevent manganese-induced apoptosis in PC12 cells. NEPP11 can activate Nrf2 and maintain MEK1/2 and ERK1/2 activity by inhibiting c-Raf downregulation. NEPP11 exerts a neuroprotective effect in a mouse model of focal cerebral ischemia caused by permanent middle cerebral artery occlusion.

NEP108 is a GID4 E3 ligase-based BRD4 PROTAC degrader, with its DC50 value approximately 3.8 μM. NEP108 has a strong affinity for GID4, with a KD value of 0.22 μM, and the KD value of its trimeric complex is 2.85 μM. NEP108 can be used for cancer research. (Pink: BRD4 ligand ; Blue: Ligands for E3 Ligase ligand ; Black: linker).

Neoambrosin is a sesquiterpene lactone. Neoambrosin acts as a partial agonist of PPARγ and TRPA1 receptors, with no carbonic anhydrase inhibitory activity. Neoambrosin can be used in research on hypoglycemia, analgesia, anti-inflammation and anticancer effects.

NEK7 degrader-3 is an orally active and brain-penetrant NEK7 molecular glue degrader with a DC50 of 33.1 nM. NEK7 degrader-3 mediates interaction between NEK7 and E3 ligase cereblon, promoting proteasomal degradation of NEK7 and attenuating NLRP3 inflammasome-mediated inflammatory responses. NEK7 degrader-3 inhibits caspase-1 activity, cytokine release of IL-1β, IL-1α, and IL-18, and pyroptotic plasma membrane permeabilization. NEK7 degrader-3 shows antiinflammatory activity in an LPS-induced neuroinflammation mouse model. NEK7 degrader-3 can be used for the research of neuroinflammation.

NecroX-5 free base is a derivative of the NecroX, reduces intracellular calcium concentration, and possesses anti-inflammatory and anti-cancer activity.

Necopidem (Compound 6) is a GABA A receptor modulator. Necopidem can be used in research on neurological disorders such as anxiety.

Nebracetam (WEB 1881 FU) is an orally active M1 muscarinic receptor agonist. Nebracetam can induce an increase in intracellular Ca2+ concentration, with an EC50 value of 1.59 mM. Nebracetam exhibits neuroprotective activity and the ability to improve cognitive impairment. Nebracetam can be used in the research of neurological diseases such as Alzheimer's disease.

N-Desmethylsertraline-13C6 (Sertraline impurity 30-13C6) is the 13C-labeled N-Desmethylsertraline.

N-Desmethyl xanomeline is a pharmacologically active metabolite of Xanomeline. N-Desmethyl xanomeline binds to muscarinic, serotonergic, histaminergic and dopaminergic receptors. N-Desmethyl xanomeline can be used for the research of schizophrenia.

N-Descyclopropanecarbaldehyde olaparib-CO-C9-NHBoc (Compound 6h) is a target protein ligand-linker conjugate that can be used for the synthesis of PROTACs, such as PROTAC PARP2 degrader-1.

N-Deacetylcolchicine tartrate is a microtubule polymerization inhibitor with an IC50 of 3 μM against bovine brain microtubules. N-Deacetylcolchicine tartrate is a derivative of Colchicine. N-Deacetylcolchicine tartrate can activate the GTPase activity of microtubules and can be used for the research of cancer.

ND-654 is a highly selective acetyl-CoA carboxylase (ACC) inhibitor (IC50: ACC1=3 nM, ACC2=8 nM). ND-654 reduces hepatic lipogenesis, decreases neutrophil recruitment and promotes anti-inflammatory M2 macrophage polarization. ND-654 is promising for research of nonalcoholic steatohepatitis and hepatocellular carcinoma.

NCT-10b (compound 17b) is a selective HDAC6 inhibitor.NCT-10b mediates preferential α-tubulin acetylation without major histone H4 acetylation.NCT-10b can be used for the research of multiple myeloma.

NCO-650 free base is an antiallergic agent that acts by inhibiting tryptase, a key trypsin-like protease in mast cells. NCO-650 free base inhibits mast cell histamine release, increases intracellular cAMP levels in mast cells, suppresses bronchoconstriction, and prevents decreases in perfusion pressure and systemic blood pressure. NCO-650 free base is applicable to the research of allergic diseases and bronchial asthma.

N-Cholyl-L-leucine is a bile acid-amino acid conjugate, mainly produced by intestinal microorganisms. N-Cholyl-L-leucine can be used as a biomarker for premature infants and is also employed in the study of bile acid metabolism.

N-Chloroacetyl-L-tryptophan (Chloroacetyltryptophan) is a hydrolyzable tryptophan derivative. N-Chloroacetyl-L-tryptophan rapidly hydrolyzes to tryptophan in Pseudomonas aurantiaca cultures. N-Chloroacetyl-L-tryptophan increases the level of the antibiotic Pyrrolnitrin in Pseudomonas aurantiaca fermentation cultures.

NBI 30545 is a blood-brain barrier permeable CRF1R antagonist with a Ki value of 3.4 nM for the human receptor. NBI 30545 inhibits CRF-stimulated intracellular cAMP accumulation and ACTH release. NBI 30545 can be used in the research of depression, anxiety disorders and stress-related diseases.

N-Benzylsulfamide is a benzyl-substituted sulfamide reagent. N-Benzylsulfamide can be used as a synthetic precursor to generate dioxides of bicyclic thiadiazines.

NBD Sphingosine-1-phosphate (ammonium) is a sphosphingolipid.

NB-7 (example 12) is a potent and orally active SARM1 inhibitor with an IC50 < 1 μM. NB-7 can be used for neurological disorders research.

NB-216 is an orally active and brain-penetrant BACE-1 inhibitor (IC50 = 17 nM). NB-216 has a strong inhibitory effect on cathepsin D (IC50 = 1 nM) and cathepsin E (IC50 = 0.4 nM). NB-216 can be used for the study of Alzheimer's disease.

Nav1.8-IN-22 (Formula I) is a Nav1.8 sodium channel inhibitor. Nav1.8-IN-22 regulates sodium channel activity by directly binding to Nav1.8. Nav1.8-IN-22 is applicable for pain-related research.

Nav1.8-IN-21 is a potent and selective Nav1.8 inhibitor with analgesic activity. Nav1.8-IN-21 can be used for analgesia Research.

Nav1.7-IN-19 is a potent, selective and orally active Nav1.7 inhibitor with an IC50 of 0.49 μM. Nav1.7-IN-19 shows high selectivity for Nav1.7, with selectivities of 312-fold and 662-fold against Nav1.1 and Nav1.5 in the inactivated state. Nav1.7-IN-19 exhibits weak inhibition on hERG potassium channels. Nav1.7-IN-19 exhibits analgesic effect and can be used for the research of neurological disease.

NAT8L-IN-1 is a NAT8L inhibitor with an IC50 value of 0.3 μM. NAT8L-IN-1 can be used for the research of Canavan disease.

Naproxen methyl ester is a prodrug of Naproxen and an ester derivative. Naproxen methyl ester is promising for research of arthritis and other inflammatory conditions1.

Nandinine is an orally active derivative of Berberine. Nandinine enhances AMPK activity, inhibits the activation of IKKβ/NF-κB, and regulates the phosphorylation of IRS-1. Nandinine reverses the abnormal production of adipokines, promotes insulin-mediated glucose uptake, and alleviates insulin resistance. Nandinine improves glucose tolerance and increases the insulin sensitivity index in mice. Nandinine can be used in studies related to insulin resistance.